Immunotherapy in managing metastatic melanoma: which treatment when?
Explore this paper's citation graph
Summary
The late evidence for targeted and immunotherapy in melanoma patients, as well as therapy sequencing are discussed, and there are still unanswered questions of the best therapy sequence, the clear superiority of combined immunotherapy versus monotherapy in all patients, and therapy duration.
- Type
- review
- Published
- 2017-09-17
- Cited by
- 14
- References
- 118
- OpenAlex
- https://openalex.org/W2752333919
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:46835615
Keywords
Medicine, Immunotherapy, Melanoma, Clinical trial, Targeted therapy
References
- Achievements and challenges of molecular targeted therapy in melanoma.
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.
- Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.
- Shaping the repertoire of tumor-infiltrating effector and regulatory T cells
- Cancer and the chemokine network
- Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
- MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells
- New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
- The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
- Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Adaptive immunity maintains occult cancer in an equilibrium state
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies.
- B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.
Cited by
- Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing’s sarcoma family of tumors (ESFT)
- Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey
- Chemoresistance mechanisms of breast cancer and their countermeasures.
- Overexpression of RACK1 Predicts Poor Prognosis in Melanoma
- Suppression of tumor growth and metastasis by ethanol extract of Angelica dahurica Radix in murine melanoma B16F10 cells.
- Decoding novel mechanisms and emerging therapeutic strategies in breast cancer resistance.
- BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis
- Treatment of BRAF-Mutated Metastatic Melanoma: Immunotherapy or Target Therapy?
- Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges
- Drug dependence in cancer is exploitable by optimally constructed treatment holidays
- Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
- Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review.
- Pan-Cancer Analysis of ANO6 and Experimental Validation in Metastatic Melanoma
- Augmenting MEK inhibitor Efficacy in BRAF Wild-Type Melanoma: Synergistic Effects of Disulfiram Combination Therapy
- Drug dependence in cancer is exploitable by optimally constructed treatment holidays
- Mechanisms and intervention strategies of tumor chemoresistance
Related papers
- Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients.
- Inhibition of leukocyte migration in agarose by KC1 extracts of a human melanoma cell line grown in serum‐free medium
- The melanoma epidemic: more apparent than real?
- Commentary: High-metastatic melanoma cells promote the metastatic capability of low-metastatic melanoma cells via exosomal transfer of miR-411-5p
- Epidermotropic metastatic malignant melanoma.
- Analysis of BRAF Mutation in Primary and Metastatic Melanoma
- [The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study].
- Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma
- Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma
- Immunotherapy or targeted therapy as first-line treatment of patients with advanced/metastatic melanoma with the BRAF mutation — a single-center analysis